Biologics Platform Targets T Cell-Mediated Diseases in Oncology and Autoimmunity Experienced Management Team, Board of Directors and Scientific Advisory Board Named CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc. (Cue), an immunotherapy company developing biologics engineered to
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc. (Cue), an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced today that it will participate in this year's BIO CEO & Investor
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc. (Cue), an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced the appointment of three new key opinion leaders to its
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc. (Cue), an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced today that it will present at the 5 th Annual Cancer Biopartnering &
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc. (Cue), an immunotherapy company developing biologic therapeutics engineered to selectively target and modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced the selection of its lead candidate, Cue-101,
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc., an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, today announced that Kenneth Pienta, M.D., will serve as acting Chief Medical Officer
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc., an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced today that it will present at the 2017 BIO International Convention being
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc., an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune diseases, today announced that Mary Simcox, Ph.D., will serve as the Vice President of
Agreement Focuses on Development of Next-Generation Biologics to Selectively Modulate T Cell Activity for the Treatment of Autoimmune Diseases CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma ™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to
CAMBRIDGE, MA, Dec 5, 2017 – Cue Biopharma™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, today announced the appointment of Colin Sandercock as Senior Vice President and General Counsel.